BSE - Delayed Quote INR

Zydus Lifesciences Limited (ZYDUSLIFE.BO)

Compare
956.60
-32.20
(-3.26%)
At close: 3:30:00 PM GMT+5:30
Currency in INR All numbers in thousands
Download
Breakdown
TTM
3/31/2024
3/31/2023
3/31/2022
3/31/2021
Total Revenue
208,702,000.00
190,215,000.00
168,778,000.00
148,276,000.00
141,250,000.00
Cost of Revenue
64,097,000.00
65,004,000.00
65,589,000.00
58,189,000.00
50,708,000.00
Gross Profit
144,605,000.00
125,211,000.00
103,189,000.00
90,087,000.00
90,542,000.00
Operating Expense
90,770,000.00
79,816,000.00
74,640,000.00
65,320,000.00
63,168,000.00
Operating Income
53,835,000.00
45,395,000.00
28,549,000.00
24,767,000.00
27,374,000.00
Net Non Operating Interest Income Expense
471,000.00
776,000.00
-541,000.00
-511,000.00
-1,146,000.00
Pretax Income
56,431,000.00
48,089,000.00
25,897,000.00
28,381,000.00
23,992,000.00
Tax Provision
13,442,000.00
9,775,000.00
5,878,000.00
5,117,000.00
1,936,000.00
Net Income Common Stockholders
43,030,000.00
38,595,000.00
19,603,000.00
44,873,000.00
21,336,000.00
Diluted NI Available to Com Stockholders
43,030,000.00
38,595,000.00
19,603,000.00
44,873,000.00
21,336,000.00
Basic EPS
42.66
38.14
19.30
43.83
20.84
Diluted EPS
42.66
38.14
19.30
43.83
20.84
Basic Average Shares
1,008,910.58
1,011,926.84
1,015,649.87
1,023,742.60
1,023,742.60
Diluted Average Shares
1,008,910.58
1,011,926.84
1,015,649.87
1,023,742.60
1,023,742.60
Rent Expense Supplemental
--
261,000.00
229,000.00
206,000.00
215,000.00
Total Expenses
154,867,000.00
144,820,000.00
140,229,000.00
123,509,000.00
113,876,000.00
Net Income from Continuing & Discontinued Operation
43,030,000.00
38,595,000.00
19,603,000.00
44,873,000.00
21,336,000.00
Normalized Income
41,862,842.89
37,522,058.54
29,455,892.54
20,281,492.55
24,011,814.27
Interest Income
--
1,268,000.00
757,000.00
688,000.00
495,000.00
Interest Expense
745,000.00
440,000.00
1,255,000.00
1,144,000.00
1,559,000.00
Net Interest Income
471,000.00
776,000.00
-541,000.00
-511,000.00
-1,146,000.00
EBIT
57,176,000.00
48,529,000.00
27,152,000.00
29,525,000.00
25,551,000.00
EBITDA
65,666,000.00
56,170,000.00
34,379,000.00
36,886,000.00
32,799,000.00
Reconciled Cost of Revenue
64,097,000.00
65,004,000.00
65,589,000.00
58,189,000.00
50,708,000.00
Reconciled Depreciation
8,490,000.00
7,641,000.00
7,227,000.00
7,361,000.00
7,248,000.00
Net Income from Continuing Operation Net Minority Interest
42,777,000.00
38,365,000.00
19,649,000.00
22,416,000.00
22,016,000.00
Total Unusual Items Excluding Goodwill
1,200,000.00
1,058,000.00
-5,001,000.00
2,604,000.00
-2,171,000.00
Total Unusual Items
1,200,000.00
1,058,000.00
940,000.00
2,604,000.00
-2,171,000.00
Normalized EBITDA
64,466,000.00
55,112,000.00
33,439,000.00
34,282,000.00
34,970,000.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
285,842.89
215,058.54
-1,135,107.46
469,492.55
-175,185.73
3/31/2021 - 7/18/2001

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

4887.T Sawai Group Holdings Co., Ltd.
2,027.00
+0.67%
 
4540.T Tsumura & Co.
4,528.00
+0.33%
 
600079.SS HUMANWELL HEALTHCARE
21.89
-0.27%
 
4530.T Hisamitsu Pharmaceutical Co., Inc.
4,642.00
+0.04%
 
4521.T Kaken Pharmaceutical Co., Ltd.
4,292.00
+1.35%
 
600085.SS TONGRENTANG
36.75
+0.14%
 
AUROPHARMA.BO Aurobindo Pharma Limited
1,211.85
-2.69%
 
ALKEM.BO Alkem Laboratories Limited
5,026.80
-2.95%
 
940.F Euroapi S.A.
3.0900
+0.26%
 
000999.SZ China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.
44.18
+0.61%